Owen F, Bourne R, Crow T J, Johnstone E C, Bailey A R, Hershon H I
Arch Gen Psychiatry. 1976 Nov;33(11):1370-3. doi: 10.1001/archpsyc.1976.01770110098010.
Platelet monoamine oxidase (MAO) activity was investigated in a series of 60 patients with chronic schizophrenic illnesses free from neuroleptic medication, and 70 normal controls. No significant differences in platelet MAO activity or in substrate preference were detected between patients and controls, using tryptamine and tyramine as substrates. Platelet MAO activity did not distinguish patients with positive symptoms from those with negative symptoms alone and did not show any relationship with severity of disease or with a number of clinical features. These findings suggest that low platelet MAO activity cannot be regarded as a genetic marker for schizophrenia. Important determinants of platelet MAO activity yet to be discovered may have contributed to the discrepancies in recent observations of platelet MAO activity in schizophrenia.
对60例未服用抗精神病药物的慢性精神分裂症患者及70名正常对照者进行了血小板单胺氧化酶(MAO)活性研究。以色胺和酪胺为底物时,未检测到患者与对照者在血小板MAO活性或底物偏好方面存在显著差异。血小板MAO活性无法区分仅有阳性症状的患者与仅有阴性症状的患者,且与疾病严重程度或多种临床特征均无关联。这些发现表明,血小板MAO活性降低不能被视为精神分裂症的遗传标记。血小板MAO活性尚未被发现的重要决定因素可能导致了近期精神分裂症患者血小板MAO活性观察结果的差异。